Iodixanol Nasal Solution Reduces Allergic Rhinoconjunctivitis Signs and Symptoms in Allergen BioCube®: Randomized Clinical Trial

Published On: October 05, 2018 | Pages: 001 - 008

Author(s): Gomes PJ*, Abelson MB, Stein L, Viirre E, Villafranca JE and Lasser EC

Importance: Allergic rhinitis affects about 20% of the population worldwide. Available pharmacological treatments are helpful but not ideal in providing relief; safer and more effective treatments are needed. Objective: To evaluate the efficacy and safety of Nasapaque nasal solution vs placebo for relief or prophylactic treatment of seasonal allergic rhinitis.